BioSpace

China tightens grip on biotech platform ownership but foreign licensing deals still okay

The new policy signals an escalation by the Chinese government on biopharma deals but is unlikely to have a major impact given that the vast majority of foreign interest in Chinese biotech comes in the form of licensing agreements.

By BioSpace

1 min read
China tightens grip on biotech platform ownership but foreign licensing deals still okay
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights